Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW)
TWD 28.8
(-1.54%)
TWD 28.8
(-1.54%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 939.54 Million TWD | 209.13% |
| 2022 | 303.93 Million TWD | -45.56% |
| 2021 | 558.3 Million TWD | 486.8% |
| 2020 | -144.33 Million TWD | -118.15% |
| 2019 | 795.07 Million TWD | 14.86% |
| 2018 | 692.22 Million TWD | -33.06% |
| 2017 | 1.03 Billion TWD | 181.64% |
| 2016 | 367.16 Million TWD | -0.76% |
| 2015 | 369.96 Million TWD | -60.19% |
| 2014 | 929.23 Million TWD | 32.99% |
| 2013 | 698.74 Million TWD | 5.89% |
| 2012 | 659.85 Million TWD | 1520.66% |
| 2011 | -46.44 Million TWD | 83.16% |
| 2010 | -275.78 Million TWD | -191.39% |
| 2009 | 301.78 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 1.2 Billion TWD | 28.41% |
| 2024 Q2 | 795.4 Million TWD | -34.07% |
| 2023 Q4 | 939.54 Million TWD | 2.08% |
| 2023 FY | 939.54 Million TWD | 209.13% |
| 2023 Q1 | 618.13 Million TWD | 103.38% |
| 2023 Q3 | 920.35 Million TWD | 77.07% |
| 2023 Q2 | 519.77 Million TWD | -15.91% |
| 2022 Q2 | 318.69 Million TWD | -35.63% |
| 2022 Q1 | 495.11 Million TWD | -11.32% |
| 2022 FY | 303.93 Million TWD | -45.56% |
| 2022 Q4 | 303.93 Million TWD | -11.68% |
| 2022 Q3 | 344.11 Million TWD | 7.97% |
| 2021 Q1 | -197.87 Million TWD | -37.09% |
| 2021 FY | 558.3 Million TWD | 486.8% |
| 2021 Q3 | 550.38 Million TWD | 257.52% |
| 2021 Q4 | 558.3 Million TWD | 1.44% |
| 2021 Q2 | 153.94 Million TWD | 177.8% |
| 2020 Q3 | -189.37 Million TWD | 41.94% |
| 2020 FY | -144.33 Million TWD | -118.15% |
| 2020 Q1 | 781.3 Million TWD | -1.73% |
| 2020 Q2 | -326.16 Million TWD | -141.75% |
| 2020 Q4 | -144.33 Million TWD | 23.78% |
| 2019 Q3 | 817.2 Million TWD | 15.26% |
| 2019 Q4 | 795.07 Million TWD | -2.71% |
| 2019 FY | 795.07 Million TWD | 14.86% |
| 2019 Q1 | 737.49 Million TWD | 6.54% |
| 2019 Q2 | 708.99 Million TWD | -3.86% |
| 2018 Q1 | 882.59 Million TWD | -14.65% |
| 2018 Q4 | 692.22 Million TWD | 20.69% |
| 2018 Q3 | 573.57 Million TWD | -33.26% |
| 2018 FY | 692.22 Million TWD | -33.06% |
| 2018 Q2 | 859.42 Million TWD | -2.63% |
| 2017 Q2 | 420.99 Million TWD | 24.14% |
| 2017 Q4 | 1.03 Billion TWD | 61.61% |
| 2017 FY | 1.03 Billion TWD | 181.64% |
| 2017 Q3 | 639.86 Million TWD | 51.99% |
| 2017 Q1 | 339.11 Million TWD | -7.64% |
| 2016 Q4 | 367.16 Million TWD | -18.76% |
| 2016 FY | 367.16 Million TWD | -0.76% |
| 2016 Q3 | 451.96 Million TWD | 40.16% |
| 2016 Q2 | 322.45 Million TWD | 0.43% |
| 2016 Q1 | 321.07 Million TWD | -13.21% |
| 2015 FY | 369.96 Million TWD | -60.19% |
| 2015 Q2 | 335.07 Million TWD | -11.52% |
| 2015 Q1 | 378.67 Million TWD | -59.25% |
| 2015 Q4 | 369.96 Million TWD | -1.56% |
| 2015 Q3 | 375.84 Million TWD | 12.17% |
| 2014 Q3 | 968.56 Million TWD | 31.85% |
| 2014 FY | 929.23 Million TWD | 32.99% |
| 2014 Q4 | 929.23 Million TWD | -4.06% |
| 2014 Q2 | 734.6 Million TWD | -2.03% |
| 2014 Q1 | 749.85 Million TWD | 7.31% |
| 2013 Q3 | 706.65 Million TWD | 42.75% |
| 2013 Q4 | 698.74 Million TWD | -1.12% |
| 2013 FY | 698.74 Million TWD | 5.89% |
| 2013 Q1 | 569.28 Million TWD | -13.73% |
| 2013 Q2 | 495.01 Million TWD | -13.05% |
| 2012 FY | 659.85 Million TWD | 1520.66% |
| 2012 Q2 | 606.94 Million TWD | 2547.4% |
| 2012 Q3 | 612.53 Million TWD | 0.92% |
| 2012 Q4 | 659.85 Million TWD | 7.72% |
| 2012 Q1 | 22.92 Million TWD | 149.36% |
| 2011 Q4 | -46.44 Million TWD | -66.16% |
| 2011 Q2 | -106.99 Million TWD | 33.11% |
| 2011 Q1 | -159.96 Million TWD | 42.0% |
| 2011 FY | -46.44 Million TWD | 83.16% |
| 2011 Q3 | -27.95 Million TWD | 73.87% |
| 2010 FY | -275.78 Million TWD | -191.39% |
| 2010 Q4 | -275.78 Million TWD | 0.0% |
| 2009 FY | 301.78 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Apex Biotechnology Corp. | -201.21 Million TWD | 566.935% |
| Sinphar Pharmaceutical Co.,Ltd. | 870.53 Million TWD | -7.928% |
| Panion & Bf Biotech Inc. | 193.2 Million TWD | -386.286% |
| GenMont Biotech Incorporation | 2.71 Million TWD | -34543.953% |
| Abnova (Taiwan) Corporation | -415.8 Million TWD | 325.956% |
| Adimmune Corporation | 685.12 Million TWD | -37.134% |
| Tanvex BioPharma, Inc. | 1.35 Billion TWD | 30.457% |
| Polaris Group | -2.41 Billion TWD | 138.841% |
| Energenesis Biomedical CO.,LTD. | -246.6 Million TWD | 480.987% |
| UnicoCell Biomed Co., Ltd. | 54.43 Million TWD | -1626.151% |
| PELL Bio-Med Technology Co. Ltd. | 4.88 Million TWD | -19149.006% |